Publication

A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS: FIRST RESULTS

Yska, J. P., Punter, R. J., Woerdenbag, H. J., Apers, J. A., Emous, M., Totte, E., Frijlink, H. W., Wilffert, B. & van Roon, E. N., Oct-2014, In : British Journal of Clinical Pharmacology. 78, 4, p. 774-774 1 p.

Research output: Contribution to journalMeeting AbstractAcademic

APA

Yska, J. P., Punter, R. J., Woerdenbag, H. J., Apers, J. A., Emous, M., Totte, E., ... van Roon, E. N. (2014). A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS: FIRST RESULTS. British Journal of Clinical Pharmacology, 78(4), 774-774. https://doi.org/10.1111/bcp.12400

Author

Yska, J. P. ; Punter, R. J. ; Woerdenbag, H. J. ; Apers, J. A. ; Emous, M. ; Totte, E. ; Frijlink, H. W. ; Wilffert, B. ; van Roon, E. N. / A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS : FIRST RESULTS. In: British Journal of Clinical Pharmacology. 2014 ; Vol. 78, No. 4. pp. 774-774.

Harvard

Yska, JP, Punter, RJ, Woerdenbag, HJ, Apers, JA, Emous, M, Totte, E, Frijlink, HW, Wilffert, B & van Roon, EN 2014, 'A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS: FIRST RESULTS' British Journal of Clinical Pharmacology, vol. 78, no. 4, pp. 774-774. https://doi.org/10.1111/bcp.12400

Standard

A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS : FIRST RESULTS. / Yska, J. P.; Punter, R. J.; Woerdenbag, H. J.; Apers, J. A.; Emous, M.; Totte, E.; Frijlink, H. W.; Wilffert, B.; van Roon, E. N.

In: British Journal of Clinical Pharmacology, Vol. 78, No. 4, 10.2014, p. 774-774.

Research output: Contribution to journalMeeting AbstractAcademic

Vancouver

Yska JP, Punter RJ, Woerdenbag HJ, Apers JA, Emous M, Totte E et al. A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS: FIRST RESULTS. British Journal of Clinical Pharmacology. 2014 Oct;78(4):774-774. https://doi.org/10.1111/bcp.12400


BibTeX

@article{6e0b8ba6360041559e77cb3faf32ae6e,
title = "A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS: FIRST RESULTS",
abstract = "Introduction Roux-en-Y gastric bypass (RYGB) surgery is the most commonly performed procedure in bariatric surgery, greatly reducing stomach size and bypassing much of the small intestine. Hence it may reduce the absorption and bioavai-lability of oral medications, especially modified release products. However, the pharmacokinetics of drugs after RYGB are poorly studied. An in vitro dissolution method simulating the conditions before and after RYGB might be a valuable tool to predict the behaviour of drugs with possible bioavailability problems in vivo. The objective of this study was to develop a gastrointestinal simulation system (GISS) mimicking conditions before and after RYGB for investigating dissolution characteristics of oral medications. Methods The GISS is a dissolution method which is based on a design by Schellekens et al. [1]. The GISS enables variation in parameters which are relevant to drug release in vivo: pH, volume, transit time, osmolality and agitation. During the test an oral drug formulation is exposed to solutions simulating stomach, (duodenum) jejunum, ileum and colon in fasting and non-fasting conditions before and after RYGB. Metoprolol immediate (IR) and controlled release (CR) tablets were tested in triplo. Release profiles were determined by measuring the concentrations of metoprolol spectrophotometrically. Results The GISS is able to expose an oral dosage form to subsequent environments simulating fasting and non-fasting conditions before and after RYGB. So far, release profiles of the tested products have been studied in conditions before RYGB. In non-fasting conditions after 30 min the release of metoprolol from the IR tablet is complete. From the CR tablet after 300 min almost 30 {\%} of metoprolol is released. Conclusion A GISS has been developed to study release behaviour of medication during its passage through the gastrointestinal tract in fasting and non-fasting conditions before and after RYGB. Studies in which the situation after RYGB is simulated are in progress.",
keywords = "metoprolol, dissolution, stomach bypass, society, clinical pharmacology, simulation, diet restriction, drug therapy, tablet, bioavailability, bariatric surgery, in vitro study, agitation, pharmacokinetics, procedures, osmolality, absorption, pH, drug formulation, stomach, jejunum, ileum, stomach volume, drug dosage form, drug release, parameters, small intestine, environment, gastrointestinal tract, duodenum, bypass surgery",
author = "Yska, {J. P.} and Punter, {R. J.} and Woerdenbag, {H. J.} and Apers, {J. A.} and M. Emous and E. Totte and Frijlink, {H. W.} and B. Wilffert and {van Roon}, {E. N.}",
year = "2014",
month = "10",
doi = "10.1111/bcp.12400",
language = "English",
volume = "78",
pages = "774--774",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "WILEY",
number = "4",

}

RIS

TY - JOUR

T1 - A GASTROINTESTINAL SIMULATION SYSTEM (GISS) FOR DISSOLUTION OF DRUGS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS

T2 - FIRST RESULTS

AU - Yska, J. P.

AU - Punter, R. J.

AU - Woerdenbag, H. J.

AU - Apers, J. A.

AU - Emous, M.

AU - Totte, E.

AU - Frijlink, H. W.

AU - Wilffert, B.

AU - van Roon, E. N.

PY - 2014/10

Y1 - 2014/10

N2 - Introduction Roux-en-Y gastric bypass (RYGB) surgery is the most commonly performed procedure in bariatric surgery, greatly reducing stomach size and bypassing much of the small intestine. Hence it may reduce the absorption and bioavai-lability of oral medications, especially modified release products. However, the pharmacokinetics of drugs after RYGB are poorly studied. An in vitro dissolution method simulating the conditions before and after RYGB might be a valuable tool to predict the behaviour of drugs with possible bioavailability problems in vivo. The objective of this study was to develop a gastrointestinal simulation system (GISS) mimicking conditions before and after RYGB for investigating dissolution characteristics of oral medications. Methods The GISS is a dissolution method which is based on a design by Schellekens et al. [1]. The GISS enables variation in parameters which are relevant to drug release in vivo: pH, volume, transit time, osmolality and agitation. During the test an oral drug formulation is exposed to solutions simulating stomach, (duodenum) jejunum, ileum and colon in fasting and non-fasting conditions before and after RYGB. Metoprolol immediate (IR) and controlled release (CR) tablets were tested in triplo. Release profiles were determined by measuring the concentrations of metoprolol spectrophotometrically. Results The GISS is able to expose an oral dosage form to subsequent environments simulating fasting and non-fasting conditions before and after RYGB. So far, release profiles of the tested products have been studied in conditions before RYGB. In non-fasting conditions after 30 min the release of metoprolol from the IR tablet is complete. From the CR tablet after 300 min almost 30 % of metoprolol is released. Conclusion A GISS has been developed to study release behaviour of medication during its passage through the gastrointestinal tract in fasting and non-fasting conditions before and after RYGB. Studies in which the situation after RYGB is simulated are in progress.

AB - Introduction Roux-en-Y gastric bypass (RYGB) surgery is the most commonly performed procedure in bariatric surgery, greatly reducing stomach size and bypassing much of the small intestine. Hence it may reduce the absorption and bioavai-lability of oral medications, especially modified release products. However, the pharmacokinetics of drugs after RYGB are poorly studied. An in vitro dissolution method simulating the conditions before and after RYGB might be a valuable tool to predict the behaviour of drugs with possible bioavailability problems in vivo. The objective of this study was to develop a gastrointestinal simulation system (GISS) mimicking conditions before and after RYGB for investigating dissolution characteristics of oral medications. Methods The GISS is a dissolution method which is based on a design by Schellekens et al. [1]. The GISS enables variation in parameters which are relevant to drug release in vivo: pH, volume, transit time, osmolality and agitation. During the test an oral drug formulation is exposed to solutions simulating stomach, (duodenum) jejunum, ileum and colon in fasting and non-fasting conditions before and after RYGB. Metoprolol immediate (IR) and controlled release (CR) tablets were tested in triplo. Release profiles were determined by measuring the concentrations of metoprolol spectrophotometrically. Results The GISS is able to expose an oral dosage form to subsequent environments simulating fasting and non-fasting conditions before and after RYGB. So far, release profiles of the tested products have been studied in conditions before RYGB. In non-fasting conditions after 30 min the release of metoprolol from the IR tablet is complete. From the CR tablet after 300 min almost 30 % of metoprolol is released. Conclusion A GISS has been developed to study release behaviour of medication during its passage through the gastrointestinal tract in fasting and non-fasting conditions before and after RYGB. Studies in which the situation after RYGB is simulated are in progress.

KW - metoprolol

KW - dissolution

KW - stomach bypass

KW - society

KW - clinical pharmacology

KW - simulation

KW - diet restriction

KW - drug therapy

KW - tablet

KW - bioavailability

KW - bariatric surgery

KW - in vitro study

KW - agitation

KW - pharmacokinetics

KW - procedures

KW - osmolality

KW - absorption

KW - pH

KW - drug formulation

KW - stomach

KW - jejunum

KW - ileum

KW - stomach volume

KW - drug dosage form

KW - drug release

KW - parameters

KW - small intestine

KW - environment

KW - gastrointestinal tract

KW - duodenum

KW - bypass surgery

U2 - 10.1111/bcp.12400

DO - 10.1111/bcp.12400

M3 - Meeting Abstract

VL - 78

SP - 774

EP - 774

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -

ID: 15105341